Summary In ovarian carcinoma cells, the combination of interferon-y (IFN-y) and cisplatin (cDDP) has been reported to result in a synergistic amplification of antiproliferative activity. To assess whether IFN-y may also prevent the occurrence of cisplatin resistance, the human ovarian carcinoma cell line HTB-77 was treated repeatedly in an intermittent fashion with either cisplatin alone (HTB-77cDDP) or cisplatin plus IFN--y (HTB-77cDDP + IFN). After 8 months of treatment, both new lines (HTB-77CDDP or HTB-77CDDP + IFN) were found to be three times more resistant to cisplatin than the wild-type cells ). IFN-y could not prevent the development of cisplatin resistance. Interestingly, both HTB-77CDDP and HTB-77CDDp+IFN cells were also less IFN-y sensitive than the parental line. Both cisplatin-resistant lines expressed p1 85HER-2 and HER-2 mRNA at a higher concentration than the HTB-77w,, cells. IFN-y was in all three HTB-77 cell lines able to suppress the HER-2 message and its encoded protein. The expression of IFN-y-induced antigens, namely CA-125 and class 11 antigens of the major histocompatibility complex (HLA-DR), was markedly augmented by IFN-y in all three lines, whereby the most prominent effect was seen in HTB-77CDDP and HTB-77CDDP + IFN.
Cisplatin (cDDP) is the most commonly used agent for the treatment of ovarian cancer. Unfortunately, the clinical use of cisplatin is limited by its toxic profile and by the frequent development of resistance (Andrews and Howell, 1990) . At present, the dominant mechanism responsible for clinically acquired resistance is unclear. Possible mechanisms of resistance to platinum compounds as identified in different ovarian tumour cell lines can be divided into decreased drug accumulation, altered drug inactivation and increased repair of DNA damage (for review van der Zee et al, 1995) . Modification of proto-oncogene expression has also been considered as an interesting possibility for tumour cells to overcome the toxic effect of cisplatin (Hancock et al, 1991) . This has also been suggested more recently by Langton-Webster et al (1994) , showing that long-term exposure of HTB-77 cells to cisplatin results in a decreased expression of the proto-oncogene HER-2 (c-erb B-2, neu), which encodes an important growth factor receptor. Interferon-y (IFN-y) is another drug that is able to suppress HER-2 expression in ovarian carcinoma cells, as has been demonstrated by reduced specific RNA and pl85HER-2 levels (Marth et al, 1990) . As reduced HER-2 expression has been associated with increased cisplatin sensitivity, the interaction of IFN-y with cisplatin in vitro becomes an interesting possibility for modulation of cytotoxicity: by combining IFN-y with cisplatin we observed a synergistic effect in HTB-77 and A 2780 ovarian carcinoma cell lines and only an additive effect in OVCAR-3 ovarian carcinoma cells (Marth et al, 1989a) . The same combination has also been shown to act in a highly synergistic manner, as demonstrated by median-effect analysis, in a cisplatin-sensitive ovarian carcinoma cell line (2008) and in its tenfold cisplatin-resistant subline (2008/C 13*) (Nehme et al, 1994) . Moreover, these authors demonstrated that IFN-y sensitized the cytotoxic effect of cisplatin.
In view of this synergistic interaction and modulation of HER-2 expression by interferons and cisplatin, we were interested to know whether IFN-y could also prevent the development of cisplatin resistance. We selected HTB-77 ovarian carcinoma cells for their well-known responsiveness to cisplatin and IFN-,y as well as HER-2 overexpression (Marth et al, 1989a (Marth et al, , 1990 . By means of acute intermittent in vitro treatments with either cisplatin alone, or in combination with IFN-y, over 8 months two HTB-77 sublines were selected and characterized for their growth properties.
MATERIALS AND METHODS Substances
Recombinant DNA-derived human IFN-,y was kindly donated by Dr G Adolf, Bender, Vienna, Austria. The preparation was essentially pure and had a specific activity of 2 x 107 antiviral U per mg of protein. Cisplatin was provided by Bristol-Myers-Squibb, Vienna, Austria.
Cell culture
The human ovarian carcinoma cell line HTB-77 (also named SK-OV-3) was obtained from Dr Christian Dittrich, University of Vienna, Austria, and was cultured and passaged in Dulbecco's modified minimum essential medium containing 10% fetal bovine serum and 2 mM L-glutamine. The HTB-77CDDP and HTB77cDDP + IFN cells were developed by intermittent repeated exposure to either cisplatin (3 ig ml-') alone or a combination of IFN-y (10 ng ml-') and cisplatin (3 ,ug ml-') respectively. Cisplatin was given to both groups simultaneously for 48 h. Cell proliferation Cells were plated in 24-well tissue culture plates (Nunc, Roskilde, Denmark) and were allowed to attach overnight. The medium was changed and cisplatin or IFN-y was added in the desired concentrations. The culture medium was renewed every 3 or 4 days. After 7 days of culture, the number of cells was enumerated by means of an electronic particle counter (Coulter, Dunstable, UK).
Surface antigen expression
The expression of antigens belonging to the major histocompatibility complex class II (HLA-DR) or CA-125 was detected by a living cell radioimmunoassay as described previously (Marth et al, 1989b) . Briefly, about 50 000 cells were seeded in 96-well tissue culture plates (Nunc), and after 3 days of treatment with IFN-y (1O ng ml') the wells were washed with culture medium. The .0 E z (Yamamoto et al, 1986 (Figure 1 ). Both types of cisplatin-treated HTB-77 cells were, however, more resistant to IFN-y alone than was the wild type (P < 0.01). The IC50 could not be reached by and HTB-77CDDP + IFN cells even at the highest dose applied, namely 100 ng ml-'. We could not observe a significant difference regarding the IFN-y responsiveness between the HTB-77CDDP and HTB-77cDDP + IFN cells.
Ovarian carcinoma cells respond to an IFN-y challenge not only with reduced growth but also with the increased expression of tumour-associated antigens and antigens of the major histocompatibility complex (Marth et al, 1989a) . We were therefore interested in whether IFN-y resistance is associated with reduced antigen expression. All HTB-77 cell types analysed did not express measurable amounts of either CA-125 or HLA-DR on their surface (Table 1) . However, after incubation with IFN-y for 3 days, all three cell types exposed the tumour marker CA-125 and HLA-DR on their surface (P < 0.01 for each comparison). This increase, however, was less pronounced in HTB-77wt than in the two other cell lines. Differences in CA-125 or HLA-DR expression after IFN-y treatment between HTB-77CDDP and HTB-77CDDP + IFN were not statistically significant.
Expression of the HER-2 proto-oncogene has been shown to be suppressed by IFN-y, and this effect has been considered to be the mechanism of interferon-mediated growth inhibition (Marth et al, 1990) . We were therefore interested in whether the resistant cell lines further reduce HER-2 expression upon IFN-y treatment. Moreover, reduced expression of HER-2 in cisplatin-resistant cells British Journal of Cancer (1997) 76(10), [1328] [1329] [1330] [1331] [1332] 0 Cancer Research Campaign 1997
Cisplatin resistance and HER-2 expression 1331 has been described recently (Langton-Webster et al, 1994) . In our experiments, however, the concentration of p185HER-2 was significantly higher in either HTB-77CDDP or HTB-77CDDP + IFN cells than in the wild-type cells (Table 2) . A 3-day treatment with IFN-y resulted in a significant reduction in the concentration of the oncogene product expressed as HER-2/neu arbitrary units per mg of protein in the three cell lines. Using total RNA, two specific transcripts of the HER-2 gene of 4.5 kb and 10 kb were detected as described previously Marth et al, 1990 (Figure 2) . The RNA concentrations were lowest in HTB-77wt (100%), higher in HTB-77CDDp (145%) and highest in HTB-77CDDP + FN (192%), cells.
The addition of IFN-y resulted in a marked reduction in the detection limit of both species of transcripts (20%, 18% and 15% respectively).
DISCUSSION
Most ovarian carcinoma patients will be treated with a platinumcontaining regimen, whereby several cycles with a relatively short duration of effective drug maintenance will be administered. In agreement with Langton-Webster et al (1994) , we attempted to mimic the clinical situation by treating an ovarian carcinoma cell line with intermittent cycles of cisplatin in vitro. Moreover, in one group of cells each cycle was preceded by treatment with IFN-Y.
The results we present indicate that cisplatin-resistant variants of the HTB-77 cells can be derived using this regimen, whereby the IFN-y treatment failed in preventing the occurrence of cisplatin resistance.
Cisplatin resistance was accompanied by an increased expression of HER-2 protein and RNA levels. This finding is in agreement with earlier studies suggesting that HER-2 overexpression is associated with a poor drug response. Benz et al (1991) showed that transfection of MCF-7 breast cancer cells with HER-2 decreased sensitivity to cisplatin and tamoxifen. Similarly, Langton et al (1993) achieved increased cisplatin resistance in a human mammary cell line by transfection with HER-2. Cells in which HER-2 expression becomes elevated may attain a selective advantage in cell proliferation and thus survive chemotherapy. Moreover, in non-small-cell lung cancer cells, high levels of p185HER-2 are correlated with intrinsic chemoresistance to cisplatin and also to doxorubicin and etoposide (Tsai et al, 1996) . As in HER-2, elevated c-myc expression upon cisplatin treatment has been described (Walker et al, 1996) . Data obtained from clinical trials suggest that overexpression of HER-2 is associated with resistance to conventional doses of cytostatic agents, including cisplatin (Hayes, 1996) .
Although in this study cisplatin resistance was also associated with elevated HER-2 expression, inhibition of the expression of this oncogene by IFN-y did not restore cisplatin sensitivity. We therefore conclude that resistance is not caused by HER-2 augmentation but is only associated with it. On the other hand, down-regulation of HER-2 by antibodies recognizing the extracellular epitope of pI85HER-2 produced, in combination with cisplatin, a synergistic decrease in proliferation of breast and ovarian carcinoma cells (Arteaga et al, 1994; Pietras et al, 1994) . As interferons also down-regulate the HER-2 message (Marth et al, 1990) it is plausible that they may induce the synergistic interaction by similar mechanisms. This could also be concluded from the effects of tyrphostin AG825, a tyrosine kinase inhibitor, which reduces HER-2 activity and enhances the chemosensitivity of highp185HER-2-expressing cell lines, whereas it had little effect on the chemosensitivities of the low-p 1 85HER-2-expressing cells (Tsai et al, 1996) . For clinical trials, therefore, the combination of a substance that reduces HER-2 activity with cisplatin seems interesting. Potential candidates are p1 85HER-2 antibodies, interferons or specific tyrosine kinase inhibitors (Zhang and Hung, 1996 (Hamaguchi et al, 1993) . Our report, for the first time, also describes a crossresistance to interferons. The mechanism of this broad induction of resistance remains unknown, as for most of these substances different mediators of action have been discussed. Surprisingly, however, interferon resistance was observed for its antiproliferative activity only. The induction of CA-125 and HLA-DR expression as well as the suppression of HER-2 oncogene RNA and protein was not reduced in both cisplatin-resistant HTB-77 cell lines, indicating a lack of correlation between antigen expression and cisplatin sensitivity. This is in agreement with earlier findings indicating a dissociation of antiproliferative activity and regulation of antigen expression: an IFN-y-resistant variant of the human breast cancer cell line BT-20 responded to IFN-y challenge with augmented HLA-DR expression, whereas proliferation was not affected (Marth et al, 1987) . Recent evidence demonstrates that the response of interferon-induced genes to IFN-y depends on a cooperative role of IFN-y-responsive factors binding to the interferon-stimulated response element (ISRE) and IFN-y activated site (GAS) elements (Chon et al, 1996) . Defects in transcription factors occurring in resistant cells could result in altered binding to the different promoter regions of interferon-induced genes and thus explain selective resistance (Guille et al, 1994) . In a recent clinical trial, however, Pujade-Lauraine et al (1996) described that response to intraperitoneal IFN-y was not reduced in cisplatinresistant ovarian cancer patients. This could indicate that mechanisms other than the direct antiproliferative activity play an important role in vivo. Activation of immune effector cells, such as peritoneal macrophages, by IFN-y may be one possibility. Moreover, IFN-y induced expression of tumour-associated antigens and HLA-DR that is not reduced in cisplatin-resistant cells could increase the sensitivity of ovarian carcinoma cells to cellmediated cytotoxicity.
